9 months ago
Eris Lifesciences to Acquire Remaining 30% in Swiss Parenterals
Eris Lifesciences, a company that makes medicines, is buying the last 30% of another company called Swiss Parenterals.
They will pay ₹423 crore for this, and instead of money, they will give shares of their own company to the seller, Naishadh Shah.
Eris already owns 70% of Swiss Parenterals, which they bought last year.
They want to make more medicines together, especially ones that are safe to inject.
Naishadh Shah will become the boss of Swiss Parenterals.
Eris is also buying other medicine brands from different companies to become stronger.
They think next year will be a big year for their business outside India.
Eris Lifesciences to acquire the remaining 30% stake in Swiss Parenterals for ₹423 crore.
The transaction will be effected through a share swap with Naishadh Shah.
Eris had previously acquired up to 70% stake in Swiss Parenterals in February 2024.
Naishadh Shah will be designated as the Managing Director of Swiss Parenterals.
Eris aims to strengthen its presence in sterile injectables and augment its global value proposition.
- Who
- Eris Lifesciences and Naishadh Shah
- What
- Acquisition of remaining 30% stake in Swiss Parenterals
- Where
- India (Eris Lifesciences) and Switzerland (Swiss Parenterals)
- When
- November 25, 2025
- Why
- To strengthen presence in sterile injectables and augment global value proposition
Key facts
- Company
- Eris Lifesciences
- Subsidiary
- Swiss Parenterals Ltd
- Stake Acquired
- 30%
- Transaction Value
- ₹423 crore
- Transaction Type
- Share swap
- Seller
- Naishadh Shah
- Designated Role
- Managing Director of Swiss Parenterals
- Previous Acquisition
- Up to 70% in February 2024
Quotes
Amit Bakshi
Chairman and Managing Director of Eris Lifesciences
“FY27 promises to be a breakout year for our international business and Naishadh’s continued leadership and stewardship will be pivotal to its growth.”
thehindubusinessline.com
Naishadh Shah
Wholetime Director of Swiss Parenterals
“The Eris platform with its manufacturing capabilities in Ahmedabad and Bhopal, combined with the existing Swiss facilities, will significantly augment our value proposition to our global clientele.”
thehindubusinessline.com
